
    
      Primary objective:

      To evaluate the clinical and laboratory safety of SB-509 when given as a single treatment by
      an intramuscular injection. To determine the maximum tolerated dose (MTD) of a single
      treatment by intramuscular injection by SB-509.

      Secondary objective:

      To evaluate the lower extremity clinical effects of SB-509 treatment on lower limb diabetic
      neuropathy by symptoms, neurological examination, and lower extremity electrophysiological
      testing.
    
  